The mRNA expression data prompted us to stain tumour sections to validate immune-related expression, by which we chose seven immunophenotypical markers [CD45, CD4, CD8, FOXP3, CD79A, Kappa/Lambda (K/L) and SLAMF7] to study both T cell and B cell expression. This evidence concerns the gene PTPRC and neoplasm.